Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Report 2026

The multicancer early detection deoxyribonucleic acid (DNA) blood tests market size has grown rapidly in recent years. It will grow from $0.79 billion in 2025 to $0.9 billion in 2026 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to increasing global cancer incidence and mortality rates, limited effectiveness of late-stage cancer diagnosis methods, growing adoption of genomic sequencing technologies in oncology research, expansion of centralized cancer diagnostic laboratories, rising awareness of early cancer screening benefits among healthcare providers.

The multicancer early detection deoxyribonucleic acid (DNA) blood tests market size is expected to see rapid growth in the next few years. It will grow to $1.49 billion by 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to advancements in multi-cancer early detection liquid biopsy technologies, increasing integration of ai-based genomic interpretation platforms, growing adoption of personalized and precision oncology screening programs, expansion of preventive healthcare initiatives and population screening mandates, rising investment in biomarker discovery and cancer genomics research. Major trends in the forecast period include rising adoption of liquid biopsy-based multi-cancer screening for early detection, increasing use of circulating tumor DNA sequencing for non-invasive cancer diagnostics, growing integration of AI-driven biomarker interpretation in cancer risk prediction, expansion of population-wide preventive oncology screening programs, rising demand for minimally invasive blood-based cancer testing over traditional biopsy methods.

The increasing prevalence of cancer worldwide is expected to drive the growth of the multicancer early detection DNA blood tests market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells that can invade surrounding tissues and, in advanced stages, metastasize to other parts of the body. The prevalence of cancer is rising as global healthcare systems report higher incidence rates and advancements in screening and detection technologies enable identification of more cases at earlier stages. Multicancer early detection DNA blood tests support the increasing prevalence of cancer by offering non-invasive, blood-based screening solutions that enable early identification of multiple cancer types through circulating tumor DNA analysis, improving early diagnosis and patient outcomes. For instance, in April 2024, according to the International Agency for Research on Cancer, there were nearly 20 million new cancer cases and close to 10 million cancer-related deaths in 2022. Demographic-based projections indicated that the annual number of new cancer cases is expected to reach 35 million by 2050, representing a 77% increase compared to 2022. Therefore, the increasing prevalence of cancer worldwide is driving the growth of the multicancer early detection DNA blood tests market.

The growing awareness of preventive healthcare is expected to support the expansion of the multicancer early detection DNA blood tests market. Preventive healthcare involves medical approaches and practices aimed at preventing diseases, promoting early diagnosis, and maintaining overall health to improve long-term outcomes and reduce the likelihood of severe illnesses. Increased public health awareness campaigns, wider access to healthcare information, and a stronger focus on personalized medicine and early disease detection are contributing to the rising adoption of preventive healthcare measures. Multicancer early detection DNA blood tests contribute to preventive healthcare by providing a convenient and non-invasive screening approach capable of identifying multiple cancer types through circulating tumor DNA analysis, thereby supporting earlier intervention and improved survival outcomes. According to the Prevent Cancer Foundation, participation in preventive cancer screening programs increased by 9.3% in 2024 compared with the previous year, as reported in January 2025. As a result, growing awareness of preventive healthcare is driving demand for multicancer early detection DNA blood tests.

Leading companies operating in the multicancer early detection DNA blood tests market are focusing on developing innovative solutions, such as advancements in cell-free DNA (cfDNA) and methylation-based sequencing technologies, to address the growing demand for early, non-invasive, and multi-cancer screening solutions. Cell-free DNA-based testing refers to the analysis of fragmented DNA released into the bloodstream by tumor cells, enabling the detection of multiple cancers from a single blood sample, unlike traditional diagnostic approaches that depend on invasive biopsies or organ-specific imaging techniques. For instance, in March 2025, Gene Solutions introduced an advanced multi-cancer early detection blood test designed for population-scale screening. The test utilizes cfDNA analysis combined with machine learning algorithms to identify cancer-specific genomic and epigenomic signatures across multiple cancer types. It enables early-stage cancer detection with high predictive accuracy while minimizing false positives, making it suitable for routine health screening. Additionally, the test incorporates tumor origin prediction technology to help identify the likely source of cancer for further diagnosis and is designed to improve accessibility to early cancer detection, particularly in regions with limited screening infrastructure.

Major companies operating in the multicancer early detection deoxyribonucleic acid (dna) blood tests market are Thermo Fisher Scientific Inc., Prenetics Global Limited, Eurofins Scientific Inc., SeekIn Inc., VolitionRx Limited, Myriad Genetics Inc., Guardant Health, Freenome Holdings Inc., GENECAST Biotechnology Co. Ltd., Burning Rock Biotech Limited, Geneseeq Technology Inc., Quibim S. L., 1drop Inc., Bioneer Corporation, CellMax Life, Datar Cancer Genetics, Laboratory for Advanced Medicine Inc., Harbinger Health Inc., Norgen Biotek Corp., Singlera Genomics Inc., Elypta AB, StageZero Life Sciences, INOVIQ, AnPac Bio-Medical Science, EarlyDiagnostics, Micronoma.

North America was the largest region in the multicancer early detection DNA blood tests market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multicancer early detection deoxyribonucleic acid (DNA) blood tests market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the multicancer early detection deoxyribonucleic acid (DNA) blood tests market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multicancer early detection DNA blood tests market consists of revenues earned by entities by providing services such as cancer screening services, diagnostic testing services, genomic sequencing services, bioinformatics analysis services, laboratory testing services, and clinical interpretation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The multicancer early detection DNA blood tests market also includes sales of sequencing instruments, laboratory equipment, blood collection kits, reagents, assay kits, and sample preparation systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream laboratories, hospitals, diagnostic centers, distributors, and research institutions) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.